30 March 2022 : Clinical Research
Follow-Up of 108 Patients with Chronic Hepatitis B Virus Infection Treated with Polyethylene Glycol-Conjugated Derivatives of Interferon-Alpha and Monitoring of Off-Treatment Virological Relapse
Liyang Zhou1ABCDEF, Qin He1CEF, Xitao Liu2DEF, Xiaoan Yang3BC, Xueting Ou3EF, Bing Situ2DF, Yueping Li4DE, Xingfei Pan1DEFG*, Qihuan Xu3AEDOI: 10.12659/MSM.934785
Med Sci Monit 2022; 28:e934785
Table 1 Demographic information and clinical characteristics of the enrolled patients.
Factors | Before PEG-IFN-α regimen | After PEG-IFNα regimen |
---|---|---|
Gender, M/F | 91/17 | 91/17 |
Age, year | – | 28±8 |
Total treatment duration, month | – | 48 (48, 69) |
Total follow-up period, week | – | 245 (16, 360) |
ALT, U/L | 173 (84, 294) | 40 (28, 66) |
AST, U/L | 103 (60, 156) | 36 (27, 52) |
Quantitative value of HBsAg, COI | 5860 (2828, 7232) | 2120 (17, 6874) |
HBV DNA, log10 copies/ml | 6.8 (5.8, 7.5) | 2 (2, 2) |
Rate of HBeAg seroconversion, % | – | 75.00 (81/108) |
Rate of HBsAg seroconversion, % | – | 17.59 (19/108) |
ALT normalization rate, % | – | 60.19 (65/108) |
Peg-IFNα – pegylated interferon alfa; HBsAg – hepatitis B surface antigen; HBV – hepatitis B virus; HBeAg – Hepatitis B e antigen; ALT – alanine aminotransferase; AST – aspartate aminotransferase. |